November 22, 2009


Alan W. Partin, M.D., Ph.D.

Chairman
David Hall McConnell Professor and Chair

Urologist -in-Chief, Department of Urology,Oncology
Johns Hopkins Medical Institutions

Editor-In-Chief
Urology

Email:apartin@jhmi.edu    Instructions for patients

PUBLICATIONS/CHAPTERS

  Free access to abstracts at PubMed


  1. Mohler JL, Partin AW, Coffey DS: Correlation of prognosis to nuclear roundness and flow cytometric light scatter. Anal. Quant. Cytol. and Hist., 9(2):156-164, 1987.

  2. Mohler JL, Partin AW, Isaacs WB, Coffey DS: Time lapse videomicroscopic identification of Dunning R-3327 adenocarcinoma and normal rat prostate cells. J. Urol., 137(3):544-547, 1987.

  3. Mohler JL, Partin AW, Coffey DS: Prediction of metastatic potential by a new grading system of cell motility: Validation in the Dunning R-3327 prostatic adenocarcinoma model. J. Urol., 138(1):168-170, 1987.

  4. Mohler JL, Partin AW, Lohr WD, Coffey DS: Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system. J. Urol., 139(5):1080-1084, 1988.

  5. Mohler JL, Partin AW, Epstein JI, Lohr WD, Coffey DS: Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II standardization of methodology for histologic sections. J. Urol., 139(5):1085-1090, 1988.

  6. Mohler JL, Partin AW, Isaacs JT, Coffey DS: Metastatic potential prediction by a visual grading system of cell motility: Prospective validation in the Dunning R-3327 prostatic adenocarcinoma model. Cancer Res., 48:4312-4317, 1988.

  7. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC: Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J. Urol., 141(2):341-345, 1989.

  8. Partin AW, Isaacs JT, Treiger B, Coffey DS: Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res., 48:6050-6053, 1988.

  9. Partin AW, Pitcock RV, Walsh AC, Mohler JL, Coffey DS: Fourier analysis of cell motility: Correlation of motility with metastatic potential in the Dunning R-3327 animal model of prostate cancer. In: Prognostic Cytometry and Cytopathology of Prostate Cancer, Editors: Karr, Coffey and Gardner. Publisher: Elsevier, New York, 1-18, 1989.

  10. Mohler JL, Partin AW, Coffey DS: Cancer cell motility: A visual grading system for assessment of prognosis in prostatic carcinoma. In: Prognostic Cytometry and Cytopathology of Prostate Cancer, Editors: Karr, Coffey and Gardner. Publisher: Elsevier, New York, 337-348, 1989.

  11. Carter HB, Partin AW, Oesterling JE, Weber JP, Epstein JI, Chan DW, Rock RC, Walsh PC: The use of prostate-specific antigen in the management of patients with prostate cancer: The Johns Hopkins Experience. In: Clinical aspects of prostate cancer: Assessment of new diagnostic procedures. Editors, Catalona, Coffey, and Karr, Publisher: Elsevier, New York, 247-251, 1989.

  12. Partin AW, Schoeniger JS, Mohler JL, Coffey DS: Fourier analysis of cell motility: Correlation with metastatic potential. Proc. Nat. Acad. Science U.S.A., 86:1254-1258, 1989.

  13. Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW, Walsh PC: The influence of reversible androgen depravation on serum prostatic-specific antigen levels in men with benign prostatic hyperplasia. J. Urol., 141:987-992, 1989.

  14. Quinlan DM, Mostwin JL, Partin AW, Nelson RJ, Walsh PC: A new rat model for the study of mammalian penile erection. J. Urol., 141:656-661, 1989.

  15. Partin AW, Pitcock RV, Walsh AC, Mohler JL, Epstein JI, Coffey DS: Nuclear morphometry as a predictor of prognosis in stage A2 prostate cancer: A critical analysis. J. Urol., 142:1254-1258, 1989.

  16. Pienta KJ, Partin AW, Coffey DS: Cancer is a disease of DNA organization and dynamic cell structure. Cancer Res., 49:2525-2532, 1989.

  17. Ward WS, Partin AW, Coffey DS: DNA loop domains in mammalian spermatozoa. Chromosomal, 98:153-159, 1989.

  18. Carter HB, Partin AW, Coffey DS: Prediction of metastatic potential in an animal model of prostate cancer: Flow cytometric quantitation of cell surface charge. J. Urol., 142:1338-1341, 1989.

  19. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC: Prostate-specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143:747-752, 1989.

  20. Murphy GF, Partin AW, Maygarden SJ, Mohler JL: Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. J. Urol., 143:1103-1107, 1989.

  21. Christensen WN, Partin AW, Walsh PC, Epstein JI: Pathologic findings in stage A2 prostate cancer: Relation of tumor volume, grade and location to pathologic stage. Cancer, 65:1021-1027, 1990.

  22. Partin AW, Walsh AC, Epstein JI, Leventhal BG, Gearhart JP: Nuclear morphometry as a predictor of response to therapy in Wilms' tumor: A preliminary report. J. Urol., 144:952-954, 1990.

  23. Isaacs WB, Issacs JT, Kypriano N, Burgers JK, Alexander RB, Partin AW, Mohler JL, Marshall FF, Coffey DS: New approaches to the evaluation of the metastatic ability of renal cell and new approaches to chemotherapy. Eur. Urol., 18:33-35, 1990.

  24. Carter HB, Partin AW, Epstein JI, Chan DW, Walsh PC: The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. J. Urol., 144:1167-1170, 1990.

  25. Leonard MP, Partin AW, Epstein JI, Jeffs RD, Gearhart JP: Nuclear morphometry as a prognostic indicator for genitourinary rhabdomyosarcoma: A preliminary investigation. J. Urol., 144:1222-1226, 1990.

  26. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC: Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J. Urol., 145:405-409, 1991.

  27. Pienta KJ, Partin AW, Coffey DS: Cell motility and structural harmonics in prostate cancer. In: Molecular and Cellular Biology of Prostate Cancer. Editors, Karr and Coffey, Publisher, Plenum Press, New York, 65-72, 1991.

  28. Partin AW, Mohler JL, Coffey DS: Cell motility as an index of metastatic ability in prostate cancers: Results with an animal model and with human cancer cells. In: Therapy for Genitourinary Cancer, Editors, Lepor and Lawson, Publisher, Kluwer Academic Publ., Norwell, Mass.121-130, 1992.

  29. Mohler JL, Partin AW, Epstein JI, Becker RL, Mikel UV, Sesterhenn IA, Mostoffi FK, Gleason DF, Sharief Y, Coffey DS: Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer, 69:511-519, 1992.

  30. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, Epstein JI: Use of nuclear morphometry, Gleason histologic scoring, clinical stage and age to predict disease free survival among patients with prostate cancer. Cancer, 70:161-168, 1992.

  31. Gearhart JP, Partin AW, Leventhal B, Beckwith JB, Epstein JI: The use of nuclear morphometry to predict response to therapy in Wilms' tumor. Cancer, 69:804-808, 1992.

  32. Borland RN, Partin AW, Epstein JI, Brendler CB: The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. J. Urol., 149:272-275, 1993.

  33. Epstein JI, Pizov G, Steinberg GD, Carter HB, Pitcock RV, Partin AW, Walsh PC: Correlation of prostate cancer nuclear DNA, size, shape and Gleason grade with pathologic stage at radical prostatectomy. J. Urol., 148:87-91, 1992.

  34. Armas OA, Galina P, Pitcock RV, Partin AW, Epstein JI: Nuclear morphology of prostatic carcinoma: Comparison of computerized image analysis (CAS 200) verses video planimetry (DynaCELL). Modern Path., 4:763,1991

  35. Tardif CP, Partin AW, Epstein JI, Mohler JL: Comparison of nuclear shape in aspirated and histologic specimens of prostatic carcinoma. Analytical and Quantitative Cytology and Histology, 14:474-482, 1993.

  36. Partin AW, Carter HB, Epstein JI, Coffey DS: The biology of prostate cancer: New and future directions in predicting tumor behavior. United States and Canadian Academy of Pathology: The Long Course - Urinary Bladder and Prostate. 198-218, 1992.

  37. Tempany CM, Partin AW, Zerhouni EI, Zinreich SJ, Walsh PC: The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. The Prostate, 22:39-42, 1993.

  38. Partin AW, Crooks D, Yoo J, Beckwith JB, Epstein JI, Gearhart JP: Prediction of disease free interval in Wilms' tumor using nuclear morphometric techniques. J. Pediatric Surgery, 29:1-5, 1994.

  39. Lee BR, Partin AW, Epstein JI, Quinlan D, Gosling JA, Gearhart JP: A quantitative histologic analysis of the dilated ureter of childhood. J. Urol., 148:1482-1486, 1992.

  40. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J. Urol., 150:110-115, 1993.

  41. Borland RN, Partin AW, Epstein JI, Isaacs WB, Brendler CB: The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. J. Urol., 149: 272-275, 1993.

  42. Partin AW, Gearhart JP, Leonard MP, Leventhal BG, Yoo JK, Crooks D, Epstein JI, Beckwith JB: Use of nuclear morphometry to predict prognosis in pediatric urologic malignancies: A review. Medical and Pediatric Oncology, 21:222-229, 1993.

  43. Epstein JI, CarMichael MJ, Partin AW, Walsh PC: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinoma of the prostate with five years follow-up. J. Urol., 149:1478-1481, 1993.

  44. Partin AW, Borland RN, Epstein JI, Brendler CB: Influence of established capsular penetration on prognosis in men with clinically localized prostate cancer. J. Urol., 150:135-141, 1993.

  45. Partin AW, Getzenberg RH, Yoo JK, CarMichael MJ, Vindivich D, Epstein JI, Coffey DS: Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Research, 53:744-746, 1993.

  46. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy: The Johns Hopkins Experience after ten years. Urologic Clinics of North America, 20:713-725, 1993.

  47. Gearhart JP, Lee B, Partin AW, Gosling JA, Epstein JI: A quantitative histologic analysis of the dilated ureter of childhood II. J. Urol., 153:172-178, 1995.

  48. Walsh PC, Partin AW: The treatment of early stage prostate cancer: Radical Prostatectomy. Important Advances In Oncology, Editors, Hellman S, Rosenberg S and DiVita V, pp. 211-224, 1994.

  49. Marshall FF, Steinberg GD, Reitz BA, Pound CR, Partin AW: The surgical treatment of renal cell carcinoma into the liver or above. The Journal of Pan-American Urology, 42:243-248, 1993.

  50. Partin AW, Coffey DS: Benign and Malignant Prostatic Neoplasms: Human Studies. Laurentian Hormone Conferences, Recent Progress in Hormone Research, 49:293-331, 1994.

  51. Epner DE, Partin AW, Schalken JA, Isaacs JT, Coffey DS: The association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma. Cancer Research, 53:1995-1997, 1993.

  52. Cadeddu JA, Pearson JD, Partin AW, Epstein JI, Carter HB: Relationship between changes in prostate specific antigen and prognosis of men with prostate cancer. Urology, 42:383-389, 1993.

  53. Pound CR, Partin AW, Simons JW, Epstein JI, Marshall FF: Nuclear morphometry predicts disease recurrence for localized renal cell carcinoma: Validation and optimization. Urology, 42:243-248, 1993.

  54. Epstein JI, CarMichael MJ, Partin AW: Small high grade adenocarcinomas of the prostate in radical prostatectomy specimens performed for non-palpable disease: Pathogenic and clinical implications. J. Urol., 151:1587-1592, 1994.

  55. Partin AW, Lee BR, CarMichael MJ, Walsh PC, Epstein JI: Radical Prostatectomy for high grade disease: A re-evaluation 1993. J. Urol., 151:1583-1586, 1994.

  56. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Evaluation of serum prostatic specific antigen velocity after radical prostatectomy to distinguish local recurrence verses distant metastases. Urology, 43:649-659, 1994.

  57. Partin AW, Oesterling JE: Clinical usefulness of prostate-specific antigen: Update 1994. J. Urol., 152:1358-1368, 1994.

  58. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT: Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. The Prostate, 25:249-265, 1994.

  59. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical prostatectomy: Results at ten years. J. Urol., 152:1831-1836, 1994.

  60. Kavoussi LR, Moore RG, Partin AW, Bender J, Zenilman M, Satava R: Telerobotic assisted laparoscopic surgery: Initial laboratory and experience. Urology, 44:15-17, 1994.

  61. Gearhart JP, Lee BR, Partin AW, Epstein JI, Gosling JA: A quantitative histological evaluation of the dilated ureter of childhood II: Ectopia, posterior urethral valves and prune belly syndrome. J. Urol., 153:1172-176, 1995.

  62. Epstein JI, CarMichael MJ, Partin AW: OA-519 (fatty acid synthase) is an independent predictor of pathological stage in adenocarcinoma of the prostate. Urology, 45:81-86, 1995.

  63. Riopel MA, Polascik TJ, Partin AW, Walsh PC, Epstein JI: Radical prostatectomy in men less than 50 years old: A study of 140 cases. Uro. Onc., 1:80-83, 1995.

  64. Mohler JL, Figlesthaler WM, Xuan-Zhi Z, Partin AW, Maygarden SJ: Nuclear shape analysis for assessment of local invasion and metastases in clinically localized prostate cancer. Cancer, 74:2996-3001, 1994.

  65. Cadeddu JA, Pearson JD, Lee B, Partin AW, Epstein JI, Carter HB: Relationship between prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia. Urology, 45:795-800, 1995.

  66. Gearhart JP, Wilmann JQ, Beckwith JB, Epstein JI, Partin AW: Nuclear morphometric analysis of metastasis in Wilm's tumor after multimodal therapy: Comparison with primary tumor. Urology, 45:119-123, 1995.

  67. CarMichael MJ, Veltri RW, Partin AW, Miller MC, Epstein JI: Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J. Urol., 153,1015-1019, 1995.

  68. Veltri RW, Partin AW, Epstein JI, Marley GM, Miller CM, Singer DS, Patton KP, Criley SR, Coffey DS: Quantitative nuclear morphometry, markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and Her2/Neu immunohistochemistry for prediction of prostate cancer progression. Journal of Cellular Biochemistry, 19: 249-258, 1994.

  69. Partin AW, Carter HB: Prostate-specific antigen - Use in clinical practice, Campbells' Urology Update #10, 1994.

  70. Partin AW, Steiner MS, Hsieh K, Simons JW, Lumadue J, Carter HB, Marshall FF: Serum ferritin as a clinical marker for renal cell carcinoma: Influence of tumor volume. Urology, 45:211-217, 1995.

  71. Partin AW, Page WF, Lee BR, Sanda MG, Miller RN, Walsh PC: Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology, 44:646-650, 1994.

  72. Partin AW, Carter HB: Prostate-specific antigen in clinical practice: Use of PSA density and PSA velocity. In: Comprehensive Textbook of Genitourinary Oncology, Editors: Vogelzang NJ, Scardino PT, Shipley WU and Coffey DS, 680-683, 1994.

  73. Polascik TJ, Pound CR, Maxwell MV, Partin AW, Marshall FF: Partial nephrectomy: Indications/technique, complications and pathological findings. J. Urol., 154:1312-1318, 1995.

  74. Quinlan DM, Partin AW, Walsh PC: Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment. Urology, 46:77-82, 1995.

  75. Partin AW, Walsh PC: Surgical management of localized prostate cancer. In: Principals and Practice of Genitourinary Oncology, Editors: Raghavan D, Scher HI, Liebel SA and Lange P, 499-507, 1994.

  76. Moore RG, Partin AW, Adams JB, Kavoussi LR: Adhesion formation following transperitoneal nephrectomy: Laparoscopic versus open approach, J. Endourology, 9:277-280, 1995.

  77. Adams JB, Moore RG, Partin AW, Kavoussi LR: New laparoscopic suture device: Initial clinical experience. Urology, 46:242-245, 1995.

  78. Kavoussi LR, Moore RG, Adams JB, Partin AW: Comparison of robotic versus human laparoscopic camera control. J. Urol., 154:2134-2136, 1995.

  79. Partin AW, Oesterling JE: PSA in clinical urological practice, AUA Update Series, Lesson I, vol. XIV, pp.1-12, 1995.

  80. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, Simons JW: Selection of men at high risk of recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 45:831-838, 1995.

  81. Simons JW, Partin AW, Carducci MA, Walsh PC, Marshall FF, Sanda MG, Mohler JL, Epstein JI, Brendler CB, Piantadosi S: Efficient prostate cancer phase II study designs using a validated PSA recurrence model. Biometrics, 1995.

  82. Partin AW, Adams JB, Moore RG, Kavoussi LR: Complete robotic assisted laparoscopic urologic surgery: A preliminary report. Journal of the American College of Surgeons, 181:552-557, 1995.

  83. Partin AW, Criley SR, Subong ENP, Zincke H, Walsh PC, Oesterling JE: Standard versus age-specific PSA reference ranges among men with clinically localized prostate cancer. J. Urol., 155:1336-1339, 1996.

  84. Ben-Chaim J, Partin AW, Jeffs RD: Ureteral bladder augmentation using the lower pole ureter of a duplicated system, Urology, 47:135-137, 1996.

  85. Kavoussi LR, Moore RG, Partin AW: Medical robotics: Past, present and future. AUA Today invited article, 1995.

  86. Moore RG, Partin AW, Kavoussi LR: The role of laparoscopy in the diagnosis and treatment of prostate cancer. Seminars in Surgical Oncology, 12:139-144, 1996.

  87. Weinstein MH, Partin AW, Veltri RW, Epstein JI: Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression following radical prostatectomy. Human Pathology, 27(7):683-687, 1996.

  88. Hedican SP, Simons JW, Eisenberger MA, Chan DW, Bruzek D, Walsh PC, Armour KW, Partin AW: Skeletal alkaline phosphatase (Ostase Assay): A potential marker of osseous progression and circulating PSA expressing cells in prostate cancer. Prostate Cancer and Prostatic Diseases, 1998.

  89. Epstein JI, Partin AW, Walsh PC: Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long term follow-up. Am. J. Surg. Pathol., 20(3):286-292, 1996.

  90. Moore RG, Adams JB, Partin AW, Docimo SG, Kavoussi LR: Telementoring of genitourinary laparoscopic procedures: Inital clinical experience. Surgical Endoscopy, 10:107-110, 1996.

  91. Carter HB, Partin AW: Diagnosis and staging of prostate cancer. Campbell's Urology, Seventh Edition, 2519-2538, 1997.

  92. Partin AW, Coffey DS: Molecular biology, endocrinology and physiology of the prostate and seminal vesicles. Campbell's Urology, Seventh Edition, 1381-1428, 1997.

  93. Rees MA, Partin AW, Walsh PC: Validation of a model for predicting metastatic disease in the pelvic lymph nodes of patients with clinically localized prostate cancer. J. Urol., 1998.

  94. Smith RC, Partin AW, Epstein JI, Brendler CB: Extended follow-up of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation. J. Urol., 156:454-458, 1996.

  95. Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, Stoner E, Walsh PC: Clinical and biological characteristics of familial benign prostatic hyperplasia. J. Urol., 157:876-879, 1997.

  96. Doehring CB, Sanda MG, Partin AW, Sauvegeot J, Jou H, Beaty TH, Epstein JI, Hill G, Walsh PC: Histopathologic characterization of hereditary benign prostatic hyperplasia. Urology, 48:650-653, 1996.

  97. Lee BR, Perlman E, Partin AW, Jeffs RD, Gearhart JP: Evaluation of smooth muscle and collagen subtypes in normal newborn and those with bladder exstrophy. J. Urol., vol. 156, November 1996.

  98. Marks LS, Dorey FJ, Rhodes T, Shery ED, Rittenhouse H, Partin AW, deKernion JB: Reset of serum PSA levels after TURP: A longitudinal characterization in men with BPH. J. Urol., 156:1035-1039, 1996.

  99. Partin AW: Prostate cancer: Educating ourselves and our nonurological colleagues. J. Urol., (Editorial), 155:610-611, 1996.

  100. Niesel T, Partin AW, Walsh PC: An anatomical approach for placement of surgical drains after radical retropubic prostatectomy: Long-term effects on post-operative pain. Urology, 48:91-94, 1996.

  101. Marshall FF, Steinberg GD, Pound CR, Partin AW: Radical surgery for renal-cell carcinoma: Caval neoplastic excision, adrenalectomy, lymphaddenectomy, adjacent organ resection. World Journal of Urology, 13:159-62, 1995.

  102. Page WF, Braun MM, Partin AW, Caporaso N, Walsh PC: Heredity and prostate cancer: A study of World War II veteran twins. Prostate, 33:240-245, 1997.

  103. Carter HB, Partin AW: Can progression of prostate cancer be predicted by pre-treatment parameters? In-Press, 1996.

  104. Carter HB, Partin AW, Luderer AA, Metter EJ, Landis P, Chan DW, Fozard JL, Pearson JD: Percentage of free prostate specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology, 49:379-384, 1997.

  105. Partin AW: The free/total PSA test: How should it be used in 1997. Urology International, 4:18-19, 1997.

  106. Partin AW, Carter HB: The use of prostate specific antigen and free/total PSA in the diagnosis of localized prostate cancer. Urologic Clinics of North America, 23:531-540, 1996.

  107. Partin AW, Catalona WJ, Southwick PC, Subong ENP, Gasior GH, Chan DW: Analysis of percent free PSA for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology, 48:55-61, 1996.

  108. Silberman MA, Partin AW, Veltri RW, Epstein JI: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathological stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer, 79:772-779, 1997.

  109. Pound CR, Partin AW, Epstein JI, Walsh PC: PSA following anatomical radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urologic Clinics of North America, 24:395-406,1997.

  110. Silver RI, Partin AW, Epstein JI, Chan DW, Hutchins G, Carter HB, Jeffs RD, Gearhart JP: Prostate specific antigen in men born with bladder exstrophy. Urology, 49:253-256, 1996.

  111. Pearson JD, Luderer AA, Metter EJ, Partin AW, Chan DW, Fozard JL, Carter HB: Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology, 48:4-9, 1996.

  112. Veltri RW, Miller MC, Partin AW, Coffey DS, Epstein JI: Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology, 48:685-691, 1996.

  113. Marks LS, Partin AW, Gormley GJ, Dorsey FJ, Shery ED, Garris JD, Subong ENP, Stoner E, deKernion JB: Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplaisa. J. Urol., 157:2171-2178, 1997.

  114. Partin AW, Piantadosi S, Subong ENP, Kelly CA, Hortopan S, Chan DW, Wolfert RL, Rittenhouse HG, Carter HB: The clearance rate of serum free and total PSA following radical retropubic prostatectomy. The Prostate, 8:35-39, 1996.

  115. Pannek J, Subong ENP, Jones KA, Marschke PLS, Epstein JI, Chan DW, Carter HB, Luderer A, Partin AW: The role of free/total PSA in the prediction of final pathological stage for men with clinically localized prostate cancer. Urology, 48:51-54, 1996

  116. Cadeddu JA, Partin AW, Epstein JI, Walsh PC: Stage D1 (T1-3, N1-3, M0) prostate cancer: A case-controlled comparison of conservative treatment versus radical prostatectomy. Urology, 50:251-255, 1997.

  117. Micali S, Silver R, Kaufman HS, Douglas VD, Marley GM, Partin AW, Moore RG, Kavoussi LR, Docimo SG: Laparoscopic oliguria: Measurement of urinary N-Acetyl-Beta, D-Glucosaminidase to assess renal ischemia. J. Uro. 157:(4)402, 1997.

  118. Thiel RP, Oesterling JE, Wojno KJ, Partin AW, Chan DW, Carter HB, Stamey TA, Prestigiacomo AR, Brawer MK, Pettaway JC, Carlson GC, Luderer AA: A multicenter comparison of the diagnostic performance of free PSA. Urology, 48:45-50,1996.

  119. Ts'o PO, Pannek J, Wang Z, Lesko SA, Bova GS, Partin AW: Detection of intact prostatic cancer cells in the blood of men with prostate cancer. Urology, 49:881-885, 1997.

  120. Garcia-Schurmann JM, Partin AW, Coffey DS: Basic science issues. The molecular and cellular biology of urologic cancers. Textbook of Urological Surgery, Editors: Ritchie and Oesterling, 3-15, 1996.

  121. Moore RG, Partin AW: Point and counterpoint laparoscopic pelvic lymphadenectomy or mini laparotomy evaluation of pelvic nodal tissue for prostate cancer the case for laparoscopic pelvic lymph node dissection. Contemporary Urology, 1997.

  122. Partin AW, Carter HB: Prostate-specific antigen: Use of PSA density and PSA velocity. In: Comprehensive Textbook of Genitourinary Oncology. Editors: Vogelzang NJ, Scardino PT, Shipley WU and Coffey DS. Baltimore: Williams and Wilkins, pp. 680-684, 1996.

  123. Partin AW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, Kattan MW, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA, 277:1445-1451, May 14, 1997.

  124. Pound CR, Walsh PC, Epstein JI, Chan DW, Partin AW: Radical prostatectomy as treatment for PSA-detected stage T1C prostate cancer. World Journal of Urol., 15:373-377, 1997.

  125. Walsh PC, Partin AW: Family history facilitates the early diagnosis of prostate cancer. Cancer, 80:1871-1874, 1997.

  126. Wills ML, Hamper UM, Partin AW, Epstein JI: Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology, 49:367-373, 1997.

  127. Partin AW, Briggman JV, Subong ENP, Szaro R, Oreper A, Wiesbrock S, Meyer J, Coffey DS, Epstein JI: Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins. Urology, 50:800-808, 1997.

  128. Carducci MA, Piantadosi S, Simkin T, Pound CR, Epstein JI, Simons JW, Marshall FF, Partin AW: Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. In-Press. Urology, 1998.

  129. Pannek J, Lakshmanan Y, Pound CR, Lemkin PF, Epstein JI, Subong ENP, Partin AW: Nuclear shape and nuclear matrix protein composition in prostate and seminal vesicles. Submitted, The Prostate, 1998.

  130. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW: The use of percent free PSA for staging of men with clinically localized prostate cancer. J. Urol., 159:1238-1242, 1998.

  131. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J. Urol., 159:5-12, 1998.

  132. Lakshmanan Y, Subong ENP, Partin AW: Differential nuclear matrix protein expression in prostate cancers: Correlation with pathologic stage. J. Urol., 159:1354-1358, 1998.

  133. Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI: Ability of sextant biopsies to predict radical prostatectomy stage. Urology, 51:759-764, 1998.

  134. Pannek J, Partin AW: Prostate specific antigen: What's new in 1997. Oncology, Sept. 1273-1282, 1997.

  135. Pannek J, Rittenhouse HG, Evans CL, Finlay JA, Bruzek DJ, Cox JL, Chan DW, Subong ENP, Partin AW: The molecular forms of prostate specific antigen and human kallikrein 2 (hK 2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology, 50:715-721, 1997.

  136. Hurwitz MD, DeWeese TL, Zinreich ES, Epstein JI, Partin AW: Nuclear morphometry predicts disease free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. Submitted, Prostate Cancer-Prostate Disease 1997.

  137. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J. Urol., 159:173-178, 1998.

  138. Christens-Barry WA, Partin AW: Quantitative grading of tissue and nuclei in prostate cancer for prognosis prediction. JHAPL Technical Digest, 18:226-233, 1997.

  139. Partin AW: The clinical utility of prostate specific antigen: Critical issues for 1997. Advances in Prostate Cancer, 1-4, 1997.

  140. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong ENP, Parson RE, Gasior GH, Loveland KG, Southwick PC: Use of percent free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: Results of a prospective multicenter clinical trial of 773 men. JAMA, 279:1542-1547, 1998.

  141. Simon I, Pound CR, Partin AW, Clemens JQ, Christens-Barry WA: Automated image analysis for detecting prostatic cell boundaries and quantifying cell motility. Cytometry, 31:287-294, 1998.

  142. Partin AW: Etiology of benign prostatic hyperplasia. Chapter inProstatic Diseases, Editor Herb Lepor, Submitted 1997.

  143. Murphy GP, Maguire R, Rogers B, Partin AW, Nelp W, Troychak MJ, Ragde H, Kenny G, Barren R, Bowes V, Gregorakis AK, Holmes E, Boynton A: Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstascintTM scanning in prostatic cancer patients. The Prostate, 33:281-285, 1997.

  144. Epstein JI, Partin AW, Walsh PC: Progression following radical prostatectomy in men with gleason score 7 tumor. J. Urol., 160:97-100, 1998.

  145. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC: Influence of radical prostatectomy on serum hormone levels. In-Press J. Urol., 1998.

  146. Partin AW, Brawer MK, Subong ENP, Kelley CA, Cox JL, Bruzek DJ, Pannek J, Meyer GE, Chan DW: Multi-institutional prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer and Prostate Disease, 1:197-203, 1998.

  147. Pound CR, Partin AW, Walsh PC, Epstein JI: The influence of biopsy perineural invasion on biochemical disease-free survival after radical prostatectomy. In-Press J. Urol., 1997.

  148. Carlson GD, Calvanese CB, Partin AW: An algorithm to predict prostate cancer. Urology, 52:455-461, 1998.

  149. Pannek J, Marks LS, Pearson J, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong ENP, Kelley CA, Stoner E, Partin AW: Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J. Urol., 159:449-453, 1998.

  150. Pannek J, Partin AW: Prostate-specific antigen: 1997 update. Primary Care & Cancer, 17:17-20, 1997.

  151. Manyak MJ, Hinkle GH, Olsen JO, Burger JK, Chiacchierini RP, Partin AW, Tester JH, Neal CE, Libertino JA, Maguire RT: Immunoscintography with 111in-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer. In-Press Urology, 1998

  152. Polascik TJ, Partin AW, Pound CR, Marshall FF: Frequent occurrence of metastatic disease in patients with renal cell carcinoma and intrahepatic or supradiaphragmatic intracaval extension treated with surgery: An outcome analysis. In-Press Urology, 1998.

  153. Polascik TJ, Partin AW: Predicting pathologic stage of prostate cancer with PSA using multivariate analysis. Contemporary Urology, Nov., 76-79, 1998

  154. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: The natural history of progression to metastases and death from prostate cancer in men with PSA recurrence following radical prostatectomy. Submitted JAMA, 1999.

  155. Pannek J, Partin AW: The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Seminars in Urologic Oncology, 16:100-105, 1998.

  156. Lee BR, Silver RI, Partin AW, Epstein JI, Gearhart JP: A quantitative histological analysis of collagen sub-types: The primary obstructed and refluxing megaureter of childhood. Urology, 51:820-823, 1998.

  157. Polascik TJ, Pearson JD, Partin AW: Multivariate models as predictors of pathologic stage using gleason score, clinical stage and serum PSA. Seminars in Urologic Oncology, 16:160-171, 1998.

  158. Griffiths K, Cockett ATK, Coffey DS, Krieg M, Lee C, McKeehan W, Neal DE, Partin AW, Sant'Agnese A, Schalken J: Regulation of prostatic growth. 4th International Consultation on Benign Prostatic Hyerplasia (BPH), pp.83-128, 1997.

  159. Sokoll LJ, Partin AW, Nelson JB, Chan DW: A critical analysis of false elevations in PSA results with the Abbott AxSYM assay. In-Press The Prostate, 1999.

  160. Bova GS, Partin AW, Isaacs SD, Carter BS, Beaty TL, Isaacs WB, Walsh PC: Biological aggressiveness of hereditary prostate cancer (HPC): Long term evaluation following radical prostatectomy. In-Press J. Urol., 1997.

  161. Polascik TJ, Oesterling JE, Partin AW: Prostate-specific antigen 1998: What we have learned and where we are going part I: Clinical utility of PSA for the diagnosis of prostate cancer. AUA Update Series, pp. 210-215, 1998.

  162. Polascik TJ, Oesterling JE, Partin AW: Prostate-specific antigen 1998: What we have learned and where we are going part II: Detection, staging and monitoring of prostate cancer. AUA Update Series, pp. 218-223, 1998.

  163. Carter HB, Epstein JI, Partin AW: The influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology, 53(1):126-130, 1998.

  164. Marshall FF, Partin AW, Chan D, Gurganus R, Hortopan SC: Mini-lap radical retropubic prostatectomy: Technique and results. In-press J. Urol., 1998

  165. . Polascik TJ, Pearson JD, Partin AW: Use of multivariate models to improve prediction of pathologic stage for men with clinically localized prostate cancer. PCPD, 1:301-306, 1998.

  166. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW: Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Critical Reviews in Clinical Laboratory Sciences, 35(4):275-368, 1998.

  167. Polascik TJ, Manyak MJ, Haseman MK, Gurganus RT, Rogers B, Maguire RT, Partin AW: Comparison of clinical staging algorithms and in-capromab pendetide immunoscintography to predict lymph node involvement in high-risk prostate cancer patients. In-Press Cancer, 1998.

  168. Djavan B, Shariat S, Fakhari M, Ghawidel K, Seitz C, Partin AW, Roehrborn C, Marberger M: Neoadjuvant and adjuvant a-blockade improves early results of high-energy transurethral microwave thermotherapy for LUTS: A randomized prospective clinical trial. In-Press Urology, 1998.

  169. Polascik TJ, Hamper U, Lee BR, Dai Y, Hilton J, Magee CA, Crone JK, X V, Shue MJ, Ferrell M, Adiletta M, Partin AW: Ablation of renal tumors in a rabbit model with interstitial saline augmented radiofrequency energy: Preliminary report of a new technology. In-Press Urology, 1998.

  170. Catalona WJ, Partin AW, Slawin KM, Naughton CK, Brawer MK, Flanigan RC, Richie JP, Patel A, Walsh PC, Scardino PT, Lange PH, deKernion JB, Southwick PC, Loveland KG, Parson RE, Gasior GH: Comparison of percent free PSA in african-american and caucasian men for detection and staging of prostate cancer: A prospective multicenter clinical trial. Submitted J. Urol., 1998.

  171. Polascik TJ, Oesterling JE, Partin AW: Prostate-specific antigen, a decade of discovery: What we have learned and where we are going. Submitted J. Urol., 1998.

  172. Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, deKernion JB: Long-term effects of finasteride on prostate tissue composition. In-Press Urology, 1998.

  173. Ruska KM, Partin AW, Epstein JI, Kahane H: Prostate needle biopsy and adenocarcinoma in men under 40 years of age. In Press J. Urol., 1998.

  174. Partin AW, Catalona WJ, Finlay JA, Wang TJ, Darte C, Tindall DJ, Young CY, Klee GG, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL: The use of human glandular kallikrein 2 (hK2) for the detection of prostate cancer. In Press Urology, 1998.

  175. Lee BR, Perlman EJ, Partin AW, Jeffs RD, Gearhart JP: Evaluation of smooth muscle and collagen subtypes in the normal newborn and bladder exstrophy patient. Submitted J. Urol., 1998.

  176. Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N: a1 adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. Submitted Journal Clinical Investigation. June 30, 1998.

  177. Partin AW, Stutzman RE: Elevated PSA, abnormal prostate evaluation on DRE, and transrectal ultrasound and prostate biopsy. Urologic Clinics of North America, 25:581-589, 1998.

  178. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE, Loveland KG: Prediction of post radical prostatectomy pathology in stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial. Submitted J. Urol., 1998.

  179. Lee BR, Roberts WW, Smith DG, Eng D, Ko HW, Epstein JI, Lecksell K, Partin AW: Bioimpedance: Novel use of a minimally invasive technique for cancer localization in the intact prostate. Submitted The Prostate, 1998.

  180. Breslow NE, Partin AW, Guthrie KA, Beckwith JB, Green DM: Nuclear morphometry and prognosis in favorable histology Wilms tumor: A prospective reevaluation. Submitted J. of Clinical Onc., 1998.

  181. Potter SR, Partin AW: The clinical utility of percent free PSA: Update 1999. Submitted Contemporary Urology, 1999.

  182. Murphy GP, Partin AW: Workshop on prostate markers. Cancer, 83(10):2233-2238, 1998.

  183. Subong ENP, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW: Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. In Press The Prostate, 1998.

  184. Brawer MK, Partin AW: New prostate cancer serum markers: (percent free PSA) (human glandular kallikren-2) (N-telopeptide) (complexed PSA) (prostate-specific membrane antigen). Submitted Contemporary Urology, 1998.

  185. Polascik TJ, Wang Z, Id S, Gurganus RT, Hortopan SC, Eisenberger MA, Carducci MA, Ts'o PO, Partin AW: Harvest of intact prostate cancer cells from blood: Further characterization of a new assay. Submitted Urology, 1998.

  186. Polascik TJ, Wang Z-P, Shue MJ, Shaogie D, Gurganus RT, Hortopan SC, Ts'o POPta, Partin AW: Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells. Submitted to J. Urol., 1998.

  187. Williams AM, Simon I, Landis PK, Moser C, Christens-Barry W, Carter HB, Metter EJ, Partin AW: Prostatic growth rate determined from MRI data: Age-related longitudinal changes. Journal of Andrology, 1999.

  188. Partin AW: The Prostate. In: Cecil Textbook of Medicine, 21st Edition. Editors: Goldman L and Bennett JC. Philadelphia: W.B. Saunders Company, 1999.

  189. Partin AW: Advances in prostate cancer reported at 93rd AUA. Reviews in Urology, 2:82-91, 1999.

  190. Partin AW, Potter SR: PSA cut off, DRE, and an algorithm to repeat biopsies. Reviews in Urology, 1(1):25-26, 1999.

  191. Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher H, T'so POP: Identification and characterization of circulating prostate cancer cells. Cancer 88(12):2787-2795, 2000.

  192. Pound CR, Christens-Barry OW, Gurganus RT, Partin AW, Walsh PC: Digital rectal examination and imaging studies are unnecessary in men with an undetectable PSA following radical prostatectomy. J Urol., 162(4):1337-1340, 1999.

  193. Epstein JI, Pound CR, Partin AW, Walsh PC: Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol. 160(1):97-101, 1998.

  194. Ripple MG, Potter SR, Partin AW, Epstein JI: Needle biopsy of recurrent adenocarcinoma of the prostate following radical prostatectomy. Mod. Pathol., 13(5):521-527, 2000.

  195. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL: The use of percentage of free prostate-specific antigen to identify men with high risk for prostate cancer when PSA levels are 2-4 ng/mL and digital rectal examination is not suspicious for prostate cancer. Urology, 54(2):220-224, 1999.

  196. Pannek J, Berges RR, Sauvageot J, Lecksell KL, Partin AW: Cell turnover in human seminal vesicles and the prostate: an immunohistochemical study. Prostate Cancer and Prostatic Diseases, 2:200-203, 1999.

  197. Allard WJ, Cheli CD, Neaman IE, Goldblatt G, Smith C, Schwartz MK, Bruzek D, Morris DL, Sokoll L, Whan DW, Yeung KK, Partin AW, Brawer MK: Complexed PSA and percent free PSA provide equivalent specificity in the detection of prostate cancer. Submitted J Urol., 163:1476-1480, 1999.

  198. Reckwitz T, Potter SR, Partin AW: Prediction of loco-regional extension and metastatic disease in prostate cancer: A review. World J Urol, 18(3):165-172, 2000.

  199. Pan CC, Potter SR, Partin AW, Epstein JI: The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: A proposal to modify the Gleason grading system. Am. J Surg. Path. 24(4):563-569, 2000.

  200. Lemkin PF, Myrick JM, Lakshmanan Y, Shue MJ, Patrick JL, Hornbeck PV, Thoirnwal G, Partin AW: Exploratory data analysis groupware for qualitative and quantitative electrophoretic gel analysis over the internet - webgel. Electrophoresis, 20(18):3492-3507, 1999.

  201. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino RT, Lange PH, Gasior GH, Loveland KG, Bray KR: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology, 56(2):255-260, 2000.

  202. Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW, Partin AW: Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology, 54(5):791-795, 1999

  203. Potter SR, Partin AW: Urinary incontinence after radical retropubic prostatectomy. Review in Urology, 2:97-98, 1999

  204. Potter SR, Partin AW: Surgical therapy of clinically localized prostate cancer: rationale, patient selection, and outcomes. Prostate Cancer, 1999.

  205. Partin AW, Potter SR: Meeting review 24th annual meeting of the American Urologic Association (May 1-6, 1999 Dallas, Texas) localized prostate cancer update. Reviews in Urology, 3:124-144, 1999.

  206. Crawford ED, Batuello JT, Snow PB, Lynch J, McLeod D, Partin AW, Stock R, Stone N, Gamito EJ, Brandt J.: Use of artificial intelligence technology to predict lymph node spread for men with clinically localized prostate cancer. Cancer, 88:2105-9, 2000.

  207. Potter SR, Partin AW: NCCN 1999 Guidelines for Early Detection of Prostate Cancer. Oncology, Nov. 99-115, 1999.

  208. Epstein JI, Partin AW, Potter SJ, Walsh PC: Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology, 56(2):283-288, 2000.

  209. Reckwitz T, Potter SR, Snow PB, Zhang Z, Veltri RW, Partin AW: Artificial Neural Networks in urology: update 2000. Prostate Cancer and Prostatic Diseases, 2:222-226, 1999.

  210. Partin AW, Djavan B: 14th annual congress of the European association of urology 7-10, April 1999 Stockholm, Sweden meeting update. Reviews in Urology, 4:180-184, 1999.

  211. Djavan B, Partin AW, Hoey MF, Roehrborn G, Dixon CM, Marberger M: Transurethral radiofrequency therapy (RFT) for benign prostatic hyperplasia using a novel saline liquid conductor: the virtual electrode. Urology, 55(1):13-16, 2000.

  212. Potter SR, Partin AW: Hereditary and familial prostate cancer: biological aggressiveness and recurrence. Reviews in Urology, 2(1):35-36, 1999.

  213. Potter SR, Reckwitz T, Partin AW: The use of percent free PSA and early detection of prostate cancer. Journal of Andrology, 20(4):449-453, 1999.

  214. Weir EG, Partin AW, Epstein JI: Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol., 163(6):1739-1742, 2000.

  215. Han M, Walsh PC, Partin AW, Rodriguez R: Ability of the 1992 and 1997 American Joint Committee on Cancer (AJCC) Staging Systems for Prostate Cancer to predict progression free survival following radical prostatectomy for T2 disease. J Urol., 164(1):89-92, 2000.

  216. Simons JW, Mikhak B, Chang J, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann, MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG: Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Research, 59(20):5160-5168, 1999.

  217. Marks LS, Partin AW, Epstein JI, Tyler Ve, Simon I, Macairan ML, Chan TI, Dorey FJ, Garris JB, Veltri RW, Santos PB, Stonebrook KA, deKernion JB: Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol.,163(5):1451-1456, 2000.

  218. Saedi M, Rittenhouse H, Finlay J, Mikolajczyk S, Partin AW: The prostate-localized kallikreins: PSA and hK2. J Clinical Ligand Assay, 22(4), 371-375, 1999.

  219. Potter SR, Partin AW: Prostate Cancer: Detection, staging, and treatment of localized disease. Seminars in Roentgenology 34(4):269-283, 1999.

  220. Potter SR, Partin AW: Prostatitis syndromes and benign prostatic hyperplasia. Seminars in Roentgenology 34(4):256-268, 1999.

  221. Partin AW, Murphy GP, Brawer MK: Report on prostate cancer tumor marker workshop 1999. Cancer, 88(4):955-963, 2000.

  222. Pound CR, Partin AW: PSA recurrence: What does it mean? Current Opinions in Urology, In-Press.

  223. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan M, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H: Validation of Partin tables for predicting pathological stage of clinically confined prostate cancer. J Urol., 164(5):1591-1595, 2000.

  224. Brawer MK, Cheli CDNeaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek D, Morris DL, Sokoll L, Chan DW, Yeung KK, Partin AW, Allard WJ: Complexed PSA provides significant enhancement of specificity compared with total PSA in the detection of prostate cancer. J Urol., 163(5):1476-1480, 2000.

  225. Han M, Partin AW: Prostate Cancer in the 21st Century. Chapter IV. Anatomic radical retropubic prostatectomy for prostate cancer. Submitted 2000.

  226. Simon I, Snow PB, Marks LS, Christens-Barry WA, Epstein JI, Bluemke DA, Partin AW: Neural network prediction of prostate tissue composition based on MRI analysis: a pilot study. Submitted Analytical and Quantitative Cytology and Histology, 22(6):445-452, 2000.

  227. Vessella RL, Lange PH, Partin AW, Chan DW, Sokoll LJ, Sasse EA, Crawford ED: Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. Urology, 55(6):909-914, 2000.

  228. Han M, Snow PB, Brandt JM, Partin AW: Evaluation of artificial neural networks for the prediction of pathological stage in prostate cancer. Cancer 81(8 Suppl):1661-1666, 2001.

  229. Simon I, Partin AW: Prediction of prostate tissue composition based on MRI analysis: implications for selection of medical therapy for BPH. In-press Analytical and Quantitative Cytology and Histology, 2001.

  230. Potter SR, Epstein JI, Partin AW: Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications. Reviews in Urology, 2:190-195, 2000.

  231. Partin AW, Marks LS: Prostate specific antigen and new serum biomarkers for evaluation of chemopreventive agents. Urology, 57(Suppl4A)132-136, 2001.

  232. Marks LS, Epstein JI, Partin AW: The Role of prostate needle biopsy in evaluation of chemopreventive agents. Urology, 57(Suppl4A):191-193, 2001.

  233. Han M, Snow PB, Epstein JI, Chan TY, Jones KA, Walsh PC, Partin AW: A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors following radical prostatectomy. Urology, 56(6):994-999, 2000.

  234. Wang TJ, Linton JH, Payne J, Rittenhouse HG, Chan DW, Partin AW, Wolfert RL, Kuus-Reichel K: Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay. Hybridoma 18:535-541, 1999.

  235. Partin AW, Feneley MR: Radical retropubic prostatectomy: limitations in high-risk disease. Am. Soc. Cl. Onc. 1092-9118:303-309, 2000.

  236. Brawer MK, Abrahamsson PA, Baba S, Bostwick DG, Djavan B, Eschenbach AV, Foster CS, Lilja H, McLeod DG, Nakamura R, Partin AW, Sakr W, Schulze H: Excluding prostate cancer in men presenting with lower urinary tract symptomatology (LUTUS). Submitted 2001.

  237. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol. Clin. North Am. 28:555-565, 2001.

  238. Han M, Potter S, Partin AW: The role of free PSA in prostate cancer detection. In-press 2000.

  239. Potter SR, Partin AW: The significance of perineural invasion found on needle biopsy on the prostate: implications for definitive therapy. Reviews in Urology, 2:87-90, 2000.

  240. Han M, Pound CR, Potter S, Partin AW, Epstein JI, Walsh PC. Isolated local recurrence is rare following radical prostatectomy for men with Gleason 7 cancer and positive surgical margins: therapeutic implications. J Urol. 165(3):864-866, 2001.

  241. Snow P, Altinein J, Andersson L, Bono AV, Brandt J, Cockett A, Egevad L, Foo K, McLeod D, Partin AW. Use of artificial neural networks for diagnosis, staging and prognosis prediction for prostate cancer. Prostate Cancer 2nd Edition, 517-530, 2001.

  242. Feneley MR, Partin AW. Diagnosis of localized prostate cancer: 10 years of progress. Current Opinions in Urology, 10(4):319-327, 2000.

  243. Goluboff ET, Prager D, Rukstalis D, Giantonio B, Madorsky M, Barken IB, Partin AW, Olsson CA. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol, 166(3):882-886, 2001.

  244. Feneley MR, Partin AW. Indicators of pathological stage of prostate cancer and their use in clinical practice. Urol. Cl. North America, 28(3):443-457, 2001.

  245. Feneley MR, Partin AW: PSA and radical prostatectomy. Prostate Specific Antigen pg. 189-205, 2001.

  246. Potter SR, Partin AW: Prostate cancer tumor markers: an update on human kallikrein 2 (hK2). Reviews in Urology, 2:221-222, 2000.

  247. Batuello JT, Gamito EJ, Crawford ED, Han M, Partin AW, McLeod DG, O'Donnell C: An artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. Urology 57(3):481-485, 2001.

  248. Pound CR, Brawer MK, Partin AW: The evaluation and treatment of men with biochemical (PSA) recurrence following definitive therapy for clinically localized prostate cancer: A review. Reviews in Urology, 3(2):72-84, 2001.

  249. Reckwitz T, Subong ENP, Rittenhouse HG, Bruzek DJ, Chan DW, Sokoll LJ, Walsh PC, Partin AW: Percent free prostate-specific antigen in untreated patients with local recurrence or distant metastases following radical prostatectomy. Submitted 1999.

  250. Potter SR, Partin AW: Laparoscopic radical prostatectomy. Reviews in Urology, 3(1):22-23, 2001.

  251. Veltri RW, Miller MC, Partin AW, Poole E, Hundley RR, O'Dowd GJ: Prediction of prostate cancer stage using quantitative biopsy pathology. Cancer 91(12):2322-2328, 2001.

  252. Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW: Age, prostate-specific antigen and digital rectal exam as determinants of the probability of having prostate cancer. Urology, 57(6):1100-1104, 2001.

  253. Miller MG, O'Dowd GJ, Partin AW, Veltri RW: Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: Impact of changing disease demographics. Urology 57:1105-1111, 2001.

  254. Han M, Partin AW, Epstein JI, Walsh PC: Era-specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. In-press J Urol., 2001

  255. Han M, Piantadosi S, Zahurak ML, Sokoll LJ, Chan DW, Epstein JI, Walsh PC, Partin AW: Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57(4)707-711, 2001.

  256. Partin AW, Carter HB: A man for early detection of prostate cancer. AUA patient management problem. In-press 2001.

  257. Han M, Alfert HJ, Partin AW: Retropubic and suprapubic open prostatectomy. Campbell's Urology, Chapter 41, In-press 2001.

  258. Sakr WA, Partin AW: Intermediate endpoint biomarkers (IEB) in prostate cancer prevention trials. In-press Urology, 2001.

  259. Potter SR, Mangold LA, Shue MJ, Taylor DC, Lecksell KL, Epstein JI, Walsh PC, Partin AW: Molecular and Immunohistochemical Staging of Men with Seminal Vesicle Invasion and Negative Pelvic Lymph Nodes at Radical Prostatectomy. Cancer 89(12):2577-2586, 2000

  260. Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, Partin AW: Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? Urology 58(5):746-51, 2001.

  261. Veltri RW, Partin AW, Miller MC: Quantitative Nuclear Grade (QNG): A New Image Analysis-Based Biomarker of Clinically Relevant Nuclear Alterations. Journal of Cellular Biochemistry Suppl 35:151-157. Review, 2000.

  262. Roberts WW, Bergstralh E, Blute M, Slezak J, Carducci M, Han M, Epstein JI, Eisenberger MA, Walsh PC, Partin AW: Contemporary Identification of Patients at High Risk for Early Prostate Cancer Recurrence Following Radical Retropubic Prostatectomy. Urology 57(6):1033-1037, 2001.

  263. LaFontaine P, Chan D, Partin AW, Gurganus R, Hortopan SC, Marshall FF: Minilaparotomy radical retropubic prostatectomy: updated technique and results. Seminars in Urologic Oncology, 18(1):19-27, 2000.

  264. Eisenberger CF, Walsh PC, Eisenberger MA, Chow NH, Partin AW, Mostwin JL, Marshall FF, Epstein JI, Schoenberg M: Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. Urology 53(1):175-179, 1999.

  265. Chan TY, Partin AW, Walsh PC, Epstein JI: Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 56(5):823-827, 2000.

  266. Smith DG, Potter SR, Lee BR, Ko HW, Drummond WR, Telford JK, Partin, AW: In vivo measurement of tumor conductiveness with the magnetic bioimpedance method. IEEE Trans Biomed Eng 47(10):1403-1405, 2000.

  267. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF: Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 46 Suppl:S67-72, 2000.

  268. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58:843-848, 2001.

  269. Potter SR, Partin AW: The clinical management of prostate cancer - the surgeon's approach and outcomes. In-press 2001.

  270. Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW: Prediction of pathological stage in clinical stage T1C prostate cancer patients: The new challenge. In-press Journal of Urology 2001.

  271. Heath EI, DeWeese TL, Partin AW, DeMarzo AM, Groopman JD, Nelson WG, Rodriguez RR, Piantadosi SA, Carter HB, Schoenberg MP, Yang VW, Hugbard WC, Dannenberg AJ, Lieberman R, Walczak J, Gurganus R, Stewart J, Carducci MA. The design of a randomized, placebo-controlled trial of celecoxib in pre-prostatectomy men with clinically localized adenocarcinoma of the prostate. In-Press, The Prostate 2002.

  272. Han M, Partin AW. Nomograms for clinically localized prostate cancer. Part I. Radical prostatectomy. In Press Seminars in Urologic Oncology 2002.

  273. Gretzer MB, Partin AW. Patient selection for radical prostatectomy and prediction of pathologic stage. Cleveland Clinic Seminar 2002.

  274. Veltri RW, Miller MC, D'Dowd GJ, Partin AW: Impact of age on total and complexed PSA cutoffs in a contemporary referral series of mend with prostate cancer. Submitted Urology 2002.

  275. Haese A, Dworschack RT, Partin AW: Utilization of percent free PSA in the total PSA range 2-4ng/ml does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4-10ng/ml range. In-Press Journal of Urology 2002.

  276. Haese A, Partin AW: New serum tests for the diagnosis of prostate cancer. Drugs of Today 37(9):607-616, 2001.

  277. Haese A, Dworschack RT, Piccoli SP, Sokoll LJ, Partin AW, Chan DW: Clinical evaluation of the elecsys 1010 and 2010 systems. In-press Clinical Chemistry, 2002.

  278. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ, Brawer MK, Schwartz MK, Vessella RL, Loughlin KR, Johnston DA, Babaian RJ. Comparative analysis of complexed prostate specific antigen (PSA), free PSA, and their ratio in detecting prostate cancer. Submitted J. Urol, 2001.

  279. Partin AW: High-grade prostatic intraepithelial neoplasia on a prostate biopsy-what does it mean? In-Press Reviews in Urology 2002.

  280. Mikolajczyk SK, Marks LS Partin AW, Rittenhouse HG: Free PSA in serum is becoming more complex. Submitted 2002.

  281. Veltri RW, Miller MC, Bales WD, Fan J, Partin AW, Epstein JI, Marks LS. Saw Palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: Evidence for a possible molecular mechanism. Submitted 2002.

  282. Gretzer MB, Partin AW: PSA levels and the probability of prostate cancer on biopsy. Submitted European Urology 2001.

  283. Hlavaty JJ, Partin AW, Kusinitz F, Shue MJ, Stieg A, Bennett K, Briggman JV. Mass Spectroscopy as a discovery tool for identifying serum markers for prostate cancer. Clin. Chem. 47:1924-1926, 2001.

  284. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 166(2):416-419, 2001.

  285. Haese A, Partin AW. Nomogramme und artifizielle neuronale netzwerke in der diagnostik und zur prognose pathologischer parameter des prostatakarzinoms. German Book, In-press 2002.

  286. Partin AW. Best of the 2001 AUA annual meeting. Reviews in Urology, 3(4)193-206, 2001.

  287. Partin AW: Letter from the editor. Urology 56(1):1, 2000.

  288. Partin AW, Potter S, Carter HB: A man with an elevated PSA. Submitted book series AUA Patient Management 2001.

  289. Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan DW, Carter HB: Prostate specific antigen (PSA) predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. Submitted 2001.

  290. Sakr WA, Partin AW: Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology 57 (4 Suppl 1): 115-120, 2001.

  291. Partin AW, Rodriguez R.: The Molecular biuology, endocrinology and physiology of the prostate and seminal vesicles. Campbell's Urology Chapter 37, 2001.

  292. Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI: Prostate-specific antigen as a marker of disease activity in prostate cancer. In-press Oncology 2002.

  293. Raj GV, Partin AW, Polascik TJ. Clinical utility of 111 in-capromab pendetide immunoscintigraphy in the detection of early recurrent prostate cancer after radical prostatectomy. Submitted Cancer 2001.

  294. Potter SR, Partin AW: What you can learn from percent free PSA testing. Patient Care, 94-109, March 2000.

  295. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG: Free PSA in serum is becoming more complex. Submitted Urology 2001.

  296. O'Malley KJ, Pound CR, Walsh PC, Epstein JI Partin AW: The influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology 59(1):85-90, 2002.

  297. Haese A, Partin AW: New serum tests for the diagnosis of prostate cancer. Drugs of Today 37(9):607-616, 2001.

  298. Ellison L, Cheli C, Bright S, Veltri R, Partin AW: Cost-benefit analysis of total PSA, free/total PSA and compplexed PSA for prostate cancer screening. In-press Urology, 2002.

  299. Horninger W, Partsch G, Snow PB, Brandt JM, Partin AW: The problem of cutoff levels in a screened population: appropriateness of informing screenees about their risk of having prostate carcinoma. Cancer 91(8 Suppl):1667-1672, 2001.


  300. Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology 57(4 Suppl 1):4-27, 2001.

  301. Pannek J, Lecksell KL, Partin AW: Expression of metallothionein in seminal vesicles-an immunohistohistochemical study. Scand J Urol Nephrol 35:11-14, 2001.

  302. Partin AW: Letter from the editor. Urology 58(3):307-9, 2001.

  303. Partin AW: Prostate Cancer: Cyclooxygenase-2 as a marker for prostate cancer. Reviews in Urology 3(2):107, 2001.

  304. Han M, Partin AW: Current clinical applications of the 111 in-capromab pendetide scan (ProstaScint scan, Cyt-356). Reviews in Urology 3(4):165-171, 2001.

  305. Carter HB, Partin AW: Diagnosis and staging of prostate cancer chapter 88 Campbell's Urology 8th Edition, 2002.


  306. Haese A, Epstein JI, Huland H, Partin AW: Validation of a biopsy-based pathological algorithm to predict lymph node metastases in clinically localized prostate cancer: Impact on changing treatment modalities. Cancer 95:1016-1021, 2002.

  307. Jianfeng X, Zheng SL, Mychaleckyj J, Isaacs SD, Faith DA, Hu JJ, Sterling D, Lange E, Hawkins GA, Turner A, Ewing CM, Johnson JR, Komiya A, Bujnovsky P, Wiley KE, DeMarzo A, Chang B, Hall MC, McCullough DL, Kassabian VS, Partin AW, Carpten J, Bailey-Wilson J, Trent JM, Bleecker ER, Ohar J, Walsh PC, Isaacs WB, Meyers DA. Germline mutations and sequence variants of the Macrophage Scavenger Receptor 1 gene are associated with prostate cancer risk in Caucasian and African American men. Nature Genetics, 32:321-325, 2002.

  308. Pannek J, Partin AW: Untersuchungen zur unterschiedlichen Karzinominzidenz von prostata und samenblasen evaluation of the different cancer incidence in prostate and seminal vesicles. Aktuel Urol 33:206-212, 2002.

  309. Makarov DV, Sanderson H, Partin AW, Epstein JI: Gleason score 7 prostate cancer on needle biopsy: Is the prognostic difference in Gleason scores 4+3 and 3+4 independent of the number of involved cores?: J Urol. 167:2440-2442, 2002.

  310. Partin AW: Does sextant prostate biopsy provide adequate sampling for early detection of prostate cancer? Curr. Urol. Updates Dec;1(4):245, 2002.

  311. Harden SV, Guo Z, Epstein JI, Partin AW, Sidransky D.: Quantitative GSTP1 methylation clearly distinguishes between benign prostatic tissue and limited prostate adenocarcinoma. In-Press J.N.C.I. 2003.

  312. Gonzalgo ML, Su LM, Partin AW: Carcinoma of the prostate – diagnosis and staging. Minimally Invasive Urological Surgery Book In-press, 2003.

  313. Veltri RW, Chaudhari M, Miller MC, Poole ED, O’Dowd GJ, Partin AW,: Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage. Clinical Chemistry 48:10;1828-1834, 2002.

  314. Gretzer MB, Epstein JI, Pound CR, Walsh PC, Partin AW: Stratification of non-palpable, PSA detected (clinical stage T1c-AJCC-TNM 1992) prostatic cancer to predict biochemical recurrence. Urology, 60:1034-1039, 2002.

  315. Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Willerson G, Eisenberger M, Partin AW, Chan DW: Short-term stability of the molecular forms of PSA and effect on percent complexed PSA (cPSA) and percent free PSA. Urology, 60(Suppl 4A):24-30, 2002.

  316. Taneja SS, Hsu EI, Cheli CD, Walden P, Bartsch G, Horninger W, Babaian R, Fritsche H, Child S, Stamey T, Sokoll L, Chan DW, Brawer MK, Partin AW, Lepor H.: Complexed PSA (cPSA) as a staging tool: results based upon a multicenter prospective evaluation of CPSA in cancer diagnosis. Urology (Suppl 4A)60:10-17, 2002.

  317. Naya Y, Stamey TA, Cheli CD, Partin AW, Sokoll LK, Chan DW, Brawer MK, Taneja SS, Lepor BH, Bartsch G, Childs S, Fritsche HA, Babaian RJ: Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen. Urology, (Suppl 4A)60:36-41, 2002.

  318. Horninger W, Cheli CD, Babaian R, Fritsche BH, Lepor H, Tenaja S, Childs TS, Stamey T, Sokoll L, Chan D, Brawer MK, Partin AW, Bartsch G: Complexed PSA for early detection of prostate cancer in men with serum PSA levels of 2-4 ng/ml. Urology (Suppl 4A)60:31-35, 2002.

  319. Gretzer MB, Veltri RW, Partin AW, Chan DW: Modern tumor marker discovery in urology: surface enhanced laser desorption and ionization (SELDI). Rev in Urol. 5:81-89, 2003.

  320. Han M, Partin AW: The role of free PSA (prostate-specific antigen) and hK-2 (human Kallikrein-2 in prostate cancer detection. AUA update series 74-79, 2001.

  321. Sokoll LJ, Mangold LA, Partin AW, Epstein JI, Bruzek DJ, Dunn W, Mohr P, Wallerson G, Chan DW. Complexed prostate-specific antigen as a staging tool for prostate cancer: A prospective study in 420 men. Urology, 60(suppl 4A):18-23, 2002.

  322. Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI: Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology, Second of two parts 16(9):1218-1224, 2002.

  323. Haese A, Lija H, Vaisanen V, Pettersson K, Rittenhouse HG, Finlay JA, Partin AW, Bruzek DJ, Sokoll LJ, Chan DW. Standardization of two immunoassays for human glandular kallikrein 2 (hK2). Clin. Chem. 49:601-610, 2003.

  324. Chan TY, Mikolajczyk SD, Lecksell K, Shue MJ, Rittenhouse HG, Partin AW, Epstein JI. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology, 62:177-181 2003.

  325. Haese A, Chaudhari M, Miller MC, Epstein JI, Huland H, Palisaar J, Graefen M, Hammerer P, Poole EC, O’Dowd GJ, Partin AW, Veltri RW. Quantitative biopsy pathology for the prediction of pathologically organ confined prostate carcinoma. Cancer, 15;97(4):969-978, 2003.

  326. Li J, Zhang Z, Rosenweig J, White N, Mangold L, Partin AW, Chan DW. The prediction of organ-confined cancer with serum proteomic patterns. Submitted Cancer 2003.

  327. Partin AW, Bartsch G, Horninger W, Taneja S, Lepor H, Babaian R, Fritsche HA, Childs S, Stamey T, Sokoll L, Chan DW, Brawer MK, Thiel RP, Cheli CD. Complexed PSA improves specificity for prostate cancer detection: Results of a prospective multicenter clinical trial. In Press J. Urol. 2003.

  328. Khan MA, Partin AW. Management of high-risk populations with locally advanced prostate cancer. The Oncologist 8:259-269, 2003.

  329. Khan MA, Partin AW. Evolving role of pro-PSA as a new serum marker for the early detection of prostate cancer. Rev. In Urol. 4:198-200, 2002.

  330. Veltri RW, Partin AW, Miller MC. Quantitative nuclear grade (QNG): The clinical applications of the quantitative measurement of nuclear structure using image analysis. In: Cancer Drug Discovery and Development. Gary J. Kelloff, Ernest T. Hawk and Caroline S. Sigman, Eds. The Humana Press Inc., Totowa, NJ, 2003. (In Press)

  331. Khan MA, Partin AW. Chemoprevention and prostate cancer. In Press Rev. In Urol., 2002.

  332. Khan MA, Partin AW, Carter HB. Expectant management of localized prostate cancer. In Press Urology, 2003.

  333. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW. Pro-PSA for early detection of prostate cancer in men with a total PSA range of 4.0-10.0 ng/ml. In Press J Urol., 2003.

  334. Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel (taxotere) in the management of androgen-independent prostate cancer. Submitted J Urol., 2002.

  335. Khan MA, Partin AW. Bisphosphonates in metastatic prostate cancer. In Press Rev.In Urol., 2002.

  336. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: Update 2003. Urology, 62:86-91, 2003.

  337. Hlavaty, JJ, Partin AW, Shue MJ, Mangold LA, Derby J, Javier T, Kelley S, Stieg A, Briggman JV, Sarracino D, Hass GM, Wu Y. Identification and preliminary clinical evaluation of a 50.8kD serum marker for prostate cancer. Urology, 61:1261-1265, 2003.

  338. Gretzer MB, Partin AW. Case Scenario:54 year-old male with high grade prostatic intraepithelial neoplasia on prostate biopsy. Rev. In Urol., 5:45-48, 2003.

  339. Gretzer MB, Partin AW. Meeting Review Highlights from the 2nd International Prostate Cancer Congress St. Thomas, US Virgin Island July 2002. Rev. In Urol., 5:111-117, 2003.

  340. Childs SJ, Lugg JA, Thiel RP, Cheli CD, Brawer MK, Bartsch G, Babaian RJ, Fritsche HA, Taneja S, Lepor H, Stamey T, Sokoll LJ, Chan DW, Partin AW. Decision tree algorithms for prostate cancer detection: complexed PSA and other significant predictors using chaid analysis. In Press Urology, 2003.

  341. Khan MA, Partin AW. Partin tables: past and present. B.J. Urol. International, 92:7-11, 2003.

  342. Khan MA, Partin AW. Vasectomy and prostate cancer. In press Rev. In Urol., 2003.

  343. Khan MA, Partin AW.  Surgical margin status after radical retropubic prostatectomy.  BJU Int.,  95(3):281-284, 2005.

  344. Khan MA, Partin AW.  Tissue microarrays in prostate cancer research.  In press Rev. In Urol. 2004.

  345. Khan MA, Partin AW.  Endothelin-a receptor antagonists and advanced prostate cancer.  Submitted Rev. In press Urol., 2004.

  346. Han M, Partin AW, Chan DY, Walsh PC.  An Evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series.   J Urol. 171(1):23-6, 2004.

  347. Partin AW, Lieber ML, Marks LS, Roehrborn CG.  Serum prostate-specific antigen as a biomarker for disease progression in benign prostatic hyperplasia (BPH).  Johns Hopkins Advanced Studies in Medicine 3(4D):347-355.

  348. Gretzer MB, Partin AW.  PSA and PSA molecular derivatives.  Campbells Update, 2003.

  349. Haese A, Partin AW.  Total, complexed and free prostate-specific antigen forms and human glandular kallikrein 2: clinical application for early detection and staging of prostate cancer.  Book Klein Editor.

  350. Kalra P, Togami J, Bansal G, Partin AW, Brawer MK, Babaian RJ, Ross L, Niederberger G.  A neurocomputational model for prostate cancer detection.  Cancer 98(9):1849-54, 2003.

  351. Ellison LM, Trock BJ, Poe NR, Partin AW.  The effect of hospital volume on cancer control after radical prostatectomy.  J Urol. 173(6):2094-8, 2005.

  352. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, Partin AW, Veltri RW. Can PSA derivatives and pathological parameters predict significant change in expectant management criteria for men with prostate cancer?  J Urol. 170:2274-78, 2003.

  353. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC.  Probability of biochemical recurrence by analysis or pathologic stage, Gleason score, and margin status for localized prostate cancer.  Urology, 62(5):866-71, 2003.

  354. Gretzer M, Partin AW.  Emerging Technology presented at the 2003 AUA proteomics and SELDI.  Rev. In Urol. 5(3):156-181, 2003.

  355.      Khan MA, Walsh PC, Miller MC, Bales WD, Epstein JI, Mangold LA, Partin AW, Veltri RW.  Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.  Cancer 98(12):2583-2591, 2003.

  356.      Harden SV, Sanderson H, Goodman SN, Partin AW, Walsh PC, Epstein JI, Sidransky D.  Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies.  J of the National Cancer Institute, 95(21):1634-1637, 2003.

  357. Gretzer MB, Chan DW, vanRootselaar CL, Rosenzweig JM, Dalrymple S, Mangold LA, Partin AW, Veltri RW.  Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.  The Prostate 60(4):325-331, 2004.

  358. Bouwman K, Qui J, Zhou H, Schotanus M, Mangold LA, Vogt R, Erlandson E, Trenkle J, Partin AW, Misek D, Omenn GS, Haab BB, Hanash S.  Microarrys of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity.  Proteomics 3(11):2200-7, 2003.

  359.      Trock BJ, Brotzman M, Utz WJ, Ugarte RR, Kaplan SA, Larson TR,  Blute ML, Roehrborn CG, Partin AW.  Long-term pooled analysis of multi-center studies of cooled thermotherapy for benign prostatic hyperplasia: results at three months through four years.  Urology, 63(4):716-721, 2004.

  360. Khan MA, Partin AW.  Management of patients with an increasing prostate-specific antigen after radical prostatectomy.  Current Urology Reports, 5(3)179-187, 2004.

  361. Park J, Sokoll LJ, Bruzek DJ, Mangold L, Gurganus R, Khan MA, Partin AW, Chan DW, Veltri RW.  Assessment of PSA derivatives in a screening population of African-American, Caucasian and Korean American men.  Clinical Prostate Cancer, 2:173-176, 2004.

  362. Gretzer MG, Partin AW.  PSA markers in prostate cancer detection.  Urol. Clin N Am 30(4):677-686, 2003.

  363. Sommerfeld HJ, Partin AW, Pannek J.  Incidence of neuroendocrine cells in the seminal vesicles and the prostate – an immunohistochemical study.  International Uro and Nephrology 34:357-360, 2002.  

  364. Freedland SJ, Partin AW, Epstein JI, Walsh PC.  Biochemical failure following radical prostatectomy in men with pathologic organ confined disease: pT2a versus pT2b.  Cancer, 100(8):1646-1649, 2004.

  365.   Khan MA, Partin AW.  Finasteride and prostate cancer.  In press reviews in Urology, 2004

  366. Khan MA, Partin AW.  Vitamin D in the management of prostate cancer.  In press reviews in Urology, 2004.

  367. Freedland SJ, Mangold LA, Epstein JI, Partin AW.  Biopsy indication – A predictor of pathological stage among men with preoperative serum PSA levels <4.0 ng/mL and T1c disease.   Urology,  May;63(5):887-891, 2004.

  368. Haese A, Vaisanen V, Finlay JA, Pettersson K, Rittenhouse HG, Partin AW, Bruzek DJ, Sokoll LJ, Lilja H, Chan DW.  Standardization of two immunoassays for human glandular kallikrein 2.  Clinical Chemistry

  369.   Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton JH, Mangold LA, Mohr P, Bartsch G, Klocker H, Horninger W, Partin AW.  Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/mL total PSA range: preliminary analysis. Urology 61:274-276, 2003.

  370.   Parsons JK, Partin AW.  Applying complexed PSA (cPSA)to clinical practice.  Urology  63(5):815-818, 2004

  371. Khan MA, Partin AW.  Urological oncological emergencies.  Book chapter in press, 2004.

  372.      Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Solvin, SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AW, Logothetis C, Soule HR.  Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group.  J Clin Oncol 22(3):537-556, 2004.

  373.   Marks LS, Kojima M, Demarzo A, Heber D, Bostwick DG, Qian J, Dorey FJ, Veltri RW, Mohler JL, Partin AW.  Prostate cancer in native Japanese and Japanese-American men:  Effects of dietary differences on prostatic tissue.  Urology 64(4):765-771, 2004.

  374.   Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW.  Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate.  Clinical Cancer Research, 10:3465-3473, 2004.   

  375.   Bastian PJ, Mangold LA, Epstein JI, Partin AW.  Characteristics of insignificant clinical T1c prostate tumors.  Cancer 101(9):2001-2005, 2004.

  376. Veltri RW, Park J, Miller MC, Marks L, Kojima M, vanRootsellar C, Khan MA, Partin AW.  Stromal-epithelial measurements of prostate cancer in native Japanese and Japanese-American men.  Prostate Cancer and Prostatic Diseases 7(3):232-237, 2004.

  377. Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW.  Impact of surgical delay on long-term cancer control for clinically localized prostate cancer.  J Urology 172(5 Pt 1):1835-1839, 2004.

  378. D’Amico AV, Eisenberger MA, Partin AW, Pienta KJ.  Therapeutic strategies for patients with a rising PSA: A case-based approach.  Book Chapter, Prostate Cancer Foundation’s Report to the Nation on Prostate Cancer 2004, Published by Medscape Hematology-Oncology 2004.

  379. Rogers CG, Khan MA, Miller CM, Veltri RW, Partin AW.  Natural history of progression in patients who fail to achieve an undetectable PSA following radical prostatectomy.  Cancer, 1;101(11):2549-56, 2004.

  380. Eisenberger M, Partin AW.  Further defining the aggressive phenotype in prostate cancer.  In Press (Editorial) N.E.J.M., 2004.

  381. Rosenbaum E, Partin AW, Eisenberger MA.  Biochemical relapse after primary treatment for prostate cancer:  Studies on natural history and therapeutic considerations.  Submitted J Clinical Oncology, 2004.

  382. Truskinovsky AM, Partin AW.  Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigen.  Urology 66(3):577-81, 2005.

  383. Freedland SJ, Partin AW.  Obesity and prostate cancer detection and progression.  Rev Urol, 6(4):214-216, 2004.

  384. Semmes OJ, Feng Z, Adam B, Banez LL, Bigbee WL, Campos D, Cazares L, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin AW, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivasava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L.  Evaluation of serum protein profiling by surface-enhanced laser desorption/lonization time-of-flight mass spectrometry for the detection of prostate cancer: 1. Assessment of platform reproducibility.  Clinical Chemistry 51(1):102-112, 2005.

  385. Freedland SJ, Isaacs WB, Mangold LA, Yiu SK, Grubb KA, Partin AW, Epstein JI, Walsh PC, Platz EA.  Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.  Clinical Cancer Research, 11(8):2883-2888, 2005.

  386. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG.  Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early PSA recurrence following radical prostatectomy.  Clin Cancer Res. 1;11(11):4037-43, 2005.

  387. Freedland SJ, Partin AW.  Prostate cancer update: 2004 Highlights from the 4th international prostate cancer congress, grand Bahama Island, Bahamas.  Reviews in Uro., 7(1):41-45, 2004.

  388. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.  JAMA, 294(4):433-439, 2005.

  389. Freedland SJ, Sokoll LJ, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Epstein JI, Partin AW.  Serum leptin and pathological findings at the time of radical prostatectomy.  J Uro., 173(3):773-776, 2005.

  390. Wu CL, Rowlingson AJ, Partin AW, Kalish MA, Courpas GE, Walsh PC, Fleisher LA.  Correlation of postoperative pain to quality of recovery in the immediate postoperative period.  Reg Anesth Pain Med. 30(6):516-22, 2005.

  391. Freedland SJ, Partin AW.  Dawning of the age of chemotherapy for prostate cancer.  Reviews in Urology, 7(2):110-12, 2005.

  392. Nielsen ME, Han M, Walsh PC, Partin AW, Freedland SJ.  Body mass index and outcomes in African-American and Caucasian men following radical retropubic prostatectomy for clinically localized prostate cancer.  Submitted Urology, 2005

  393. Freedland SJ, Mangold LA, Walsh PC, Partin AW.  The PSA era is alive and well: PSA and biochemical progression following radical prostatectomy.  J Urology, 174:1276-1281, 2005.

  394. Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Partin AW.  Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy.  J Uro. 174:1266-1270, 2005.

  395. Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.  Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.  J Uro. 173(3):752-756, 2005.

  396. Parsons JK, Partin AW.  Hugh Hampton Young, benigh prostatic hyperplasia, and “the cure of prostatic obstruction”.  J Am Coll Surg. 201(5):654-5, 2005.

  397. Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Issacs WB, Epstein JI, Partin AW.  Obesity and capsular incision at the time of open retropubic radical prostatectomy.  J Urol. 174(5):1798-801, 2005.

  398. Khan MA, Partin AW.  Expectant management: an option for localized prostate cancer.  Prostate Cancer Prostatic Dis. 8(4):311-5, 2005.

  399. Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, Isaacs WB, Partin AW.  Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.  J Urol. 174(3):919-22, 2005.

  400. Wu CL, Partin AW, Rowlingson AJ, Kalish MA, Walsh PC, Fleisher LA.  Efficacy of continuous local anesthetic infusion for postoperative pain after radical retropubic prostatectomy.  Urology, 66(2):366-70, 2005.

  401. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D.  Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.  Clin Cancer Res.  1;11(23):8321-5, 2005.

  402. Freedland SJ, Partin AW.  Early hormonal therapy for prostate cancer:  The good, the bad, and the ugly.  Reviews in Urology  7(3):187-89, 2005.

  403. Freedland SJ, Partin AW. Best of the 2005 AUA Annual Meeting Highlights from the 2005 annual meeting of the American Urological Association May 21-May26, 2005, San Antonio, TX. Rev Urol, 162-163, 2005.

  404. Khan MA, Sokoll LJ, Chan DW, Mangold LA, Mohr P, Mikolajczyk SD, Linton HJ, Evans CL, Rittenhouse HG, Partin AW.  Clinical utility of proPSA and benign PSA when percent free PSA is less than 15%.  UROLOGY 64(6):1160-1164, 2004.

  405. Allaf ME, Partin AW, Carter HB. The importance of pelvic lymph node dissection in men with clinically localized prostate cancer.  Submitted Reviews in Urology, 2005.

  406. ; Nielsen M, Partin AW.  Chapter 72:The role of complexed PSA (cPSA) in prostate cancer screening.  Prostate Biopsy: Indications, Techniques and Complications. Humana Press.  In Press

  407. Kirby R, Partin AW, Feneley M, Parsons K.  Anatomic radical retropubic prostatectomy Chapter 72,  Prostate Cancer:  Principles and Practice.  In Press.

  408. Leman ES, Cannon GW, Sokoll LJ, Chan DW, Janes HE, Mangold L, Partin AW, Getzenberg RH.  Early prostate cancer antigen-2 (EPCA-2) as a novel serum specific marker for prostate cancer detection.  Submitted NEJM, 2006.

  409. Han M, Partin AW.  Multivariate models for predicting pathologic stage.  Chapter 55, Prostate Cancer, In Press.

  410. Nielsen ME, Han M, Mangold L, Humphreys E, Walsh PC, Partin AW, Freedland SJ.  Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center.  J Urol. 176(2): 515-9, 2006.

  411. Makarov DV, Humpheys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ.  Pathologic outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with PSA (2.6-4.0 ng/ml) versus PSA (4.1-6.0 mg/ml).  J Urol.176 (2) 2006

  412. Haese A, Partin AW.  Markers for adenocarcinoma of the prostate-an overview on established and potential future markers.  Book Chapter.  2005, In Press

  413. Freedland SJ, Humphreys EB, Mangold LA, Schaeffer E, Eisenberger M, Walsh PC, Partin AW.  Further defining the natural history of progression after PSA elevation following radical prostatectomy: Does PSA doubling time change over time?  J. Clinical Oncology, 2005 In Press.

  414. Freedland SJ, Partin AW.  Detecting prostate cancer using molecular markers: uPM3.  Reviews In Urology, 2005 Fall; 7(4):236-8.

  415. Gonzalgo ML, Bastian PJ, Mangold LA, Trock BJ, Epstein JI, Walsh PC, Partin AW.  Relationship between primary gleason pattern on needle biopsy and clinicopathological outcomes among men with Gleason 7 adenocarcinoma of the prostate.  UROLOGY, 67(1):115-9, 2006.

  416. Parsons JK, Brawer MK, Cheli CD, Partin AW, Djavan R.  Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/ml range of total PSA.  BJU International 94:47-50, 2004.

  417. Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, DeMarzo AM.  Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays.  Prostate 61(3):215-227, 2004.

  418. Haese A, Partin AW. Nomograms and artificial neural networks in the diagnosis of prostate cancer and for the prediction of pathological parameters.  Book Chapter, In Press 2005.

  419. Veltri RW, Khan MA, Marlow C, Miller MC, Mikolajczyk SD, Kojima M, Partin AW, Marks LS.  Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer.  UROLOGY 68:898-904, 2006.

  420. Parsons JK, Partin AW.  Clinical interpretation of prostate biopsy reports.  UROLOGY 67 (3):452-457, 2006.

  421. Rohrmann S, Fallin MD, Page WF, Reed T, Partin AW, Walsh PC, Platz EA.  RE: “Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish twin registry”.  Int. J Cancer, 1;118(3):785, 2006.

  422. Freedland SJ, Partin AW.  Prostate-specific antigen:  update 2006.  UROLOGY, 67 (3):458-460, 2006.

  423. Bajaj G.K., Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Gaver M, Carson D, Pili R, Denmeade R, Partin AW, Carducci MA, Nelson W, Eisenberger M, DeWeese TL.  A phase II study of imatinib mesylate in prostate cancer patients with evidence of biochemical relapse following definitive radical retropubic prostatectomy or radiation therapy.  UROLOGY, Submitted 2006.

  424. Bastian PJ, Gonzalgo ML, Aaronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ.  Clinical and pathological outcome after radical prostatectomy for prostate cancer with a preoperative Gleason sum 8 to 10.  Submitted, Cancer, 2006.

  425. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA.  Metabolic factors associated with benign prostatic hyperplasia.  J Clinical Endocrinology and Metabolism, In Press, 2006.

  426. Makarov DV, Partin AW.  Translation research in prostate cancer.  Reviews in Urology 8(2): 89-91, 2006.

  427. Freeland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC.  Radical Prostatectomy for Stage T3 Disease.  J Urology, In Press, 2006.

  428. Marks LS, Mazer NA, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov D, Partin AW, Bostwick DG, Macairan ML, Mostaghel E, Nelson PS. Effect of Testosterone Replacement Therapy on the Prostate tissue in men with late-onset hypogonadism: A random controlled trial.  JAMA 296: 2351-61, 2006.

  429. Alumkal JJ, Zhang Z, Humphreys E, Bennett C, Mangold L, Walsh PC, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo A, Herman JG.  Impact of DNA Methylation on the Identification of Aggressive Prostate Cancers. Submitted to Clinical Cancer Research 2007.

  430. Parsons JK, Partin AW.  Management of Rising Prostate-specific Antigen after Local Surgical
    Therapy.  Book Chapter 15C.

  431. Freeland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW.  Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.  J Urology 176: 1404-08, 2006.

  432. Rohrmann S, Fallin MD, Page WF, Reed T, Partin AW, Walsh PC, Platz EA.  Concordancerates and modifiable risk factors for lower urinary tract symptoms in twins.  Epidemiology 17: 419-27, 2006.

  433. Makarov DV, Partin AW.  The predictive capability of prostate-specific antigen kinetics.  Rev Urol 8 (1):41-43, 2006.

  434. Freedland SJ, Partin AW.  Optimal surgical management of the obese man with prostate cancer: laparoscopic or perineal radical prostatectomy.  Rev Urol 7(1)46-47, 2005.

  435. Khan MA, Carducci MA, Partin AW.  Docetaxel in androgen-independent prostate cancer: an update.  BJU Int. 94(9):1209-1210, 2004

  436. Eisenberger M, Partin AW.  Progress toward identifying aggressive prostate cancer.  N Engl J Med 351(2):180-181, 2004.

  437. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, Walsh PC.  Factors Influencing the Outcome of a Closely Followed, Contemporary Series of Hormone Naïve Men with Metastatic Prostate Cancer After Radical Prostatectomy. Submitted JCO 2007.

  438. Veltri RW, Marlow C, Khan MA, Miller MC, Epstein JI, Partin, AW.  Significant Variations in Nuclear Structure Occur Between and Within Gleason Grading Patterns, 3, 4, and 5 Determined by Digital Image Analysis. Journal of Frontiers in Bioscience, 2007.

  439. Makarov DV, Partin AW. Prostate Cancer Risk Stratification via Early PSA Testing. Reviews in Urology, In Press, 2007.

  440. Malik G, Rojahn E, Ward MD, Gretzer MB, Partin AW,  Semmes OJ, Veltri RW. SELDI Protein Profiling of Dunning R-3327 Derived Cell Lines: Identification of Molecular Markers of Cancer Progression.

  441. Duggan D, Zheng S, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Sun GLJ, Chang B, Marovich L, Wiley KE, Balter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs W, Gronberg H, Xu J, Carpten J. Two Independent genome-wide association studies of aggressive prostate cancer leads to the identifications of prostate cancer risk associated variants in the DAB2IP gene.

  442. Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI. Natural History of Organ-Confined, Gleason≤6 Prostate Cancer Following Radical Prostatectomy
 
© Copyright 2009 | All Rights Reserved | Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287